XTL Biopharmaceuticals (LSE:XTL) said on Friday it had agreed to work with private Swedish biotech firm Biostapro to develop a treatment for an infection common in hospitals.

XTL will license from Biostapro two protein targets on the cell surface of two major staphylococcal bacteria, S. Aureus and S. Epidermis.

Staphylococcal infections are responsible for more than 800,000 infections each year in the United States, Europe and Japan.

The bacteria are developing an increasing rate of resistance to antibiotics.

XTL and Biostapro aim to develop fully human monoclonal antibodies to treat the infections.

XTL said it would provide its proprietary Trimera technology, and would be responsible for clinical trials and further commercialization of the antibodies.